drugset / Trial / NCT05258110
A Study in Healthy Men to Test Whether BI 425809 Influences the Amount of Midazolam in the Blood
NaSequentialOpen-labelTreatment
Summary
In order to assess the potential impact of steady state BI 425809 on CYP3A clinically, the effect of BI 425809 on the midazolam pharmacokinetics will be evaluated. Midazolam is a recommended substrate of CYP3A4.
Timeline
- Start
- 2022-03-18
- Primary completion
- 2022-05-31
- Completion
- 2022-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iclepertin | Small molecule | 10 mg | Oral |
| Subject | Midazolam | Small molecule | 2 mg | Oral |
Indications
No indication recorded.